Apolipoprotein CIII (ApoCIII) represents a key regulator of plasma lipid metabolism and a recognized risk factor for atherosclerosis and cardiovascular diseases. Beyond the regulation of lipoprotein trafficking, ApoCIII is also involved in endothelial dysfunction and monocyte recruitment related to atherothrombosis. With tissue factor (TF) being the primary initiator of the blood coagulation cascade, we hypothesized that ApoCIII-treated monocytes could express it. Hence, human CD14(+)-monocytes and autologous neutrophils were incubated with ApoCIII and sera from human subjects containing previously measured ApoCIII amounts. By RT-qPCR and ELISA, CD14(+)-monocytes, but not neutrophils, were found to show increased mRNA expression and production of TNF alpha, IL-1 beta and IL-6 as well as TF mRNA once exposed to ultra-purified ApoCIII. By flow cytometry, CD14(+)-monocytes were found to rapidly express TF on their cell surface membrane when incubated with either ApoCIII or sera with known concentrations of ApoCIII. Finally, preincubation with specific ApoCIII-neutralizing antibodies significantly reduced the ability of most sera with known concentrations of ApoCIII to upregulate TF protein, other than partially inhibiting cytokine release, in CD14(+)-monocytes. In sum, herein we demonstrate that ApoCIII activates CD14(+)-monocytes to express TF. The data identify a potential mechanism which links circulating apolipoproteins with inflammation and atherothrombosis-related processes underlying cardiovascular risk.

CD14+-Monocytes Exposed to Apolipoprotein CIII Express Tissue Factor

Olivieri, Oliviero
;
Gasperini, Sara;Calzetti, Federica;Gardiman, Elisa;Castagna, Annalisa;Martinelli, Nicola;Tamassia, Nicola;Cassatella, Marco A
2023-01-01

Abstract

Apolipoprotein CIII (ApoCIII) represents a key regulator of plasma lipid metabolism and a recognized risk factor for atherosclerosis and cardiovascular diseases. Beyond the regulation of lipoprotein trafficking, ApoCIII is also involved in endothelial dysfunction and monocyte recruitment related to atherothrombosis. With tissue factor (TF) being the primary initiator of the blood coagulation cascade, we hypothesized that ApoCIII-treated monocytes could express it. Hence, human CD14(+)-monocytes and autologous neutrophils were incubated with ApoCIII and sera from human subjects containing previously measured ApoCIII amounts. By RT-qPCR and ELISA, CD14(+)-monocytes, but not neutrophils, were found to show increased mRNA expression and production of TNF alpha, IL-1 beta and IL-6 as well as TF mRNA once exposed to ultra-purified ApoCIII. By flow cytometry, CD14(+)-monocytes were found to rapidly express TF on their cell surface membrane when incubated with either ApoCIII or sera with known concentrations of ApoCIII. Finally, preincubation with specific ApoCIII-neutralizing antibodies significantly reduced the ability of most sera with known concentrations of ApoCIII to upregulate TF protein, other than partially inhibiting cytokine release, in CD14(+)-monocytes. In sum, herein we demonstrate that ApoCIII activates CD14(+)-monocytes to express TF. The data identify a potential mechanism which links circulating apolipoproteins with inflammation and atherothrombosis-related processes underlying cardiovascular risk.
2023
apolipoprotein CIII
atherosclerosis
monocytes
thrombosis
tissue factor
File in questo prodotto:
File Dimensione Formato  
Olivieri 2023 IJMS.pdf

solo utenti autorizzati

Tipologia: Versione dell'editore
Licenza: Creative commons
Dimensione 2.12 MB
Formato Adobe PDF
2.12 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1090886
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact